Press Room

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren^® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

BLAINVILLE, QC (CANADA), January 16, 2019 — Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.

Medunik Canada is pleased to announce the launch of NORD Founder Abbey Meyers’ memoir, “Orphan Drugs: A Global Crusade”

BLAINVILLE, QC (Canada) – February 16, 2016 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce the launch of Orphan Drugs: A Global Crusade, the memoir of Abbey Meyers, founder and past President of the National Organization for Rare Disorders (NORD). In anticipation of Rare Disease Day on February 29th, Medunik Canada would like to bring to light the hard work and commitment of orphan drug crusaders, like Ms. Meyers.

PHEBURANE^® now available for distribution in Canada through Medunik Canada

BLAINVILLE, QC (Canada) – March 30th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE® is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

Medunik Canada is pleased to announce that Health Canada has granted market authorization for Pheburane^®

BLAINVILLE, QC (Canada) – January 27th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) for PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of urea cycle disorders (UCD), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Canadians living with a urea cycle disorder will now have access to an approved tasteless medication for the treatment of this metabolic disease.

Medunik Canada announces Health Canada Priority Review of PHEBURANE^® indicated for the treatment of Urea Cycle Disorders (UCD)

BLAINVILLE, QC (Canada) – September 24th, 2014 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, announces that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of Urea Cycle Disorders (UCD), was granted a Priority Review Status by Health Canada. This treatment will provide Canadians living with a urea cycle disorder access to a lower-cost alternative solution for the treatment of this metabolic disease.

Recent